Dr. Dreicer on Next-Generation AR Therapies in CRPC

Video

In Partnership With:

Robert Dreicer, MD, MS, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer.

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses the development of next-generation anti-androgen therapies for patients with castration-resistant prostate cancer (CRPC).

Dreicer says developing next-generation androgen receptor (AR) therapies is challenging because many have similar activity to drugs that are already approved. For example, orteronel, an androgen synthesis inhibitor, was unable to meet its primary endpoint of improvement in overall survival compared with placebo in a phase III trial.

In order to gain approval, new AR-targeted drugs must be dramatically better than the drugs that are already available, Dreicer says.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD